Hematopoietic growth factors: personalization of risks and benefits - Wikidata - wikimedia - TriplyDB

Hematopoietic growth factors: personalization of risks and benefits

Hematopoietic growth factors: personalization of risks and benefits

http://www.wikidata.org/entity/Q26866922

about

Physical performance limitations in adolescent and adult survivors of childhood cancer and their siblings.Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.Tissue engineering and regenerative medicine in musculoskeletal oncology.

P2860

Q34452359-31566B3E-6270-4ECC-A749-421C50E60DDF Q35121535-F6160879-1B41-4E30-BF47-8C2B72615331 Q38938423-EF55AF18-CA26-401B-A06C-832597A1A376

P2860

Hematopoietic growth factors: personalization of risks and benefits

http://www.wikidata.org/entity/Q26866922

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Hematopoietic growth factors: personalization of risks and benefits

@ast

Hematopoietic growth factors: personalization of risks and benefits

@en

Hematopoietic growth factors: personalization of risks and benefits

@nl

type

label

Hematopoietic growth factors: personalization of risks and benefits

@ast

Hematopoietic growth factors: personalization of risks and benefits

@en

Hematopoietic growth factors: personalization of risks and benefits

@nl

prefLabel

Hematopoietic growth factors: personalization of risks and benefits

@ast

Hematopoietic growth factors: personalization of risks and benefits

@en

Hematopoietic growth factors: personalization of risks and benefits

@nl

P1433

Q26866922-32A0498D-4DBC-4A82-A5C5-0BC56F7B5E59

P1476

Q26866922-02B7B1CD-6F46-4EF0-A800-F866DB4AA785

P2093

Q26866922-2E333B77-83C0-4D84-9B90-EF171DEB9B06

Q26866922-9F544944-7BA0-4722-8B78-2A6AEF04E48A

Q26866922-ED039F6E-46B5-4B6A-A408-F28497BC515C

P2860

Q26866922-020A0D2C-9A20-4A71-88CB-A0D9CC1EACAD

Q26866922-284A778D-5A4E-4F8A-BA7E-4130518BEE3B

Q26866922-301E2FF5-0B4B-4B43-9747-F2662F9633D6

Q26866922-40A4B270-204B-4299-80A7-88FAE198B879

Q26866922-43F7EAD9-FD62-43EA-892A-B37D1F538DD9

Q26866922-483AF8A6-63B9-41EA-9B87-574A78F10FD5

Q26866922-4EC2F61D-CFE5-47B9-A898-EC07C7F6F2F6

Q26866922-56DA20D7-D6B6-4988-8450-A0BEC3C8D15E

Q26866922-64CC4BFE-FEE9-4D61-BBE1-2D87C477BF30

Q26866922-6607273D-D883-4AF3-A66B-FB52F8AA111D

P304

Q26866922-B5D77183-79EF-4339-AC01-B1BDB64B517D

P31

Q26866922-AEC9B80A-E93B-45F9-8141-8EEBDCD509B3

P356

Q26866922-5350D9F5-F992-4DAC-85A8-87518BAADB12

P407

Q26866922-06D43972-2BE7-43A5-9DB2-5481059BB813

P433

Q26866922-666C2616-AAED-4F48-A993-68A5A25D17E1

P478

Q26866922-A119EE32-ED6E-4706-BB74-50914C8C9D23

P577

Q26866922-C1F71D0A-6AE0-4785-94ED-2B14239C83B9

P5875

Q26866922-16E7DF98-47D5-4796-A0A1-3D9CF6B40613

P698

Q26866922-F8B843D9-D95E-4CE5-BF48-E14E96F9DE73

P932

Q26866922-D5B8A49A-3D8C-46A9-9919-CE8737D9CD4B

P356

J.MOLONC.2012.03.001

P1433

Molecular Oncology

P1476

Hematopoietic growth factors: personalization of risks and benefits

@en

P2093

Nancy E Davidson

http://www.w3.org/2001/XMLSchema#string

Saveri Bhattacharya

http://www.w3.org/2001/XMLSchema#string

Shannon Puhalla

http://www.w3.org/2001/XMLSchema#string

P2860

Erythropoietin or Darbepoetin for patients with cancer

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma.

Functional erythropoietin autocrine loop in melanoma

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial

P304

237-241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.MOLONC.2012.03.001

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224004487

http://www.w3.org/2001/XMLSchema#string

P698

22497867

http://www.w3.org/2001/XMLSchema#string

P932

5528376

http://www.w3.org/2001/XMLSchema#string